Tina Witte

Biotech and pharma are no strangers to understanding the risks associated with innovation. In fact, their very existences are defined by feeding rich pipelines of developing new targets and thus, birthing new breeds of therapeutic classes and competitors.

It’s that time of year when school is back in session, and many families are shifting gears and reacclimating to routines after the buzz of summer vacation. The days ahead bring structure, but also a renewed sense of responsibility. Depending on their ages and stages, it’s back into the trenches of supporting, guiding, and preparing these ‘NextGens’ for what’s next. Whether it’s helping a kindergartner adjust to a new classroom or coaching a high school senior through rigorous college applicatio

The biotech and biopharma sectors are navigating an increasingly volatile terrain marked by accelerated scientific breakthroughs, evolving global regulatory dynamics, and intensifying cost-containment pressures. AI-driven changes in regulatory, shifting vaccine advisory paradigms, assertive pricing frameworks, and renewed scrutiny around IP protections are redefining the competitive environment.